Aponvie® (aprepitant) manufactured by Heron Therapeutics, Inc., a commercial- stage biotechnology company, has been approved for the prevention of postoperative nausea and vomiting (PONV) in adults.
- PONV is commonly experienced after surgery and may result in increased hospital stays, prolonged recovery time, and decreased patient satisfaction.
- Administered via a single 30-second IV injection, Aponvie is the first and only IV formulation of aprepitant for PONV prevention.
- Aponvie should not be used:
- If you are allergic to aprepitant or any of the ingredients in Aponvie
- If you are taking pimozide
- The launch date and pricing for Aponvie are pending.
